Literature DB >> 15913699

Varicella-zoster virus open reading frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells.

Huiling Hu1, Jeffrey I Cohen.   

Abstract

Varicella-zoster virus infects human dendritic cells (DCs). We found that VZV infection of DCs resulted in down-regulation of Fas expression on the surface of cells. VZV ORF47 was critical for replication of virus in human immature, but not mature DCs. Immature DCs infected with a mutant virus unable to express ORF47 expressed similar levels of a VZV immediate-early protein as cells infected with parental virus; however, cells infected with the ORF47 mutant expressed lower levels of glycoprotein E. Thus, in the absence of ORF47 protein, there is a block in viral replication between immediate-early and late gene expression. VZV unable to express ORF47 was severely impaired for spread of virus from DCs to melanoma cells. Infection of DCs with parental VZV resulted in a different pattern of phosphoproteins compared with the ORF47 mutant virus. Thus, VZV ORF47 is important for replication in immature DCs and for spread to other cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913699     DOI: 10.1016/j.virol.2005.04.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

Review 1.  Breach of the nuclear lamina during assembly of herpes simplex viruses.

Authors:  Lynda A Morrison; Gregory S DeLassus
Journal:  Nucleus       Date:  2011-07-01       Impact factor: 4.197

2.  Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Authors:  Cindy Gutzeit; Martin J Raftery; Matthias Peiser; Karsten B Tischer; Martina Ulrich; Melanie Eberhardt; Eggert Stockfleth; Thomas Giese; Andreas Sauerbrei; Craig T Morita; Günther Schönrich
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

3.  Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus.

Authors:  Stephen J Spatz; Yuguang Zhao; Lawrence Petherbridge; Lorraine P Smith; Susan J Baigent; Venugopal Nair
Journal:  Virus Genes       Date:  2007-08-25       Impact factor: 2.332

Review 4.  Varicella zoster virus immune evasion strategies.

Authors:  Allison Abendroth; Paul R Kinchington; Barry Slobedman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions.

Authors:  Stacey A Leisenfelder; Paul R Kinchington; Jennifer F Moffat
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

Review 6.  Conserved herpesvirus protein kinases.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  Biochim Biophys Acta       Date:  2007-08-16

7.  Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms.

Authors:  Amie J Eisfeld; Michael B Yee; Angela Erazo; Allison Abendroth; Paul R Kinchington
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Varicella-zoster virus open reading frame 66 protein kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells.

Authors:  Angela Erazo; Michael B Yee; Nikolaus Osterrieder; Paul R Kinchington
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

9.  ORF9p phosphorylation by ORF47p is crucial for the formation and egress of varicella-zoster virus viral particles.

Authors:  Laura Riva; Marc Thiry; Sebastien Bontems; Aline Joris; Jacques Piette; Marielle Lebrun; Catherine Sadzot-Delvaux
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

10.  Histone deacetylases 1 and 2 are phosphorylated at novel sites during varicella-zoster virus infection.

Authors:  Matthew S Walters; Angela Erazo; Paul R Kinchington; Saul Silverstein
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.